<DOC>
	<DOCNO>NCT01928511</DOCNO>
	<brief_summary>Patients Chronic Hepatitis B long term oral antiviral therapy continue treatment indefinitely unless achieve HBeAg seroconversion HBsAg seroclearance , therapy stop . While HBeAg seroconversion achievable endpoint , 20-25 % patient develop one year oral antiviral therapy . HBsAg seroclearance universally infrequent . Strategies improve endpoint combination oral antiviral therapy generally successful recently study examine possibility switch add peginterferon therapy . However test adequately group patient long term oral antiviral therapy . Consequently study conceived evaluate whether switch add peginterferon compare continue oral antiviral therapy efficacious strategy . HBeAg positive HBeAg negative patient ( n=310 ) randomise continue oral antiviral therapy , switch add pegylated interferon 48 week ratio 1:2:2 respectively . The study endpoint HBsAg seroclearance , reduction qHBsAg &gt; 1 log , qHBsAg &lt; 200 IU/ml , HBeAg loss seroconversion , HBV DNA suppression , week 72 .</brief_summary>
	<brief_title>Efficacy Switching Adding Pegylated Interferon Chronic Hepatitis B Patients Long Term Oral Antiviral Therapy</brief_title>
	<detailed_description>1 . HYPOTHESIS AND OBJECTIVES PEG-IFN immunomodulatory agent could potentiate antiviral efficacy patient long term nucleos ( ) ide analogue therapy improve early indicator efficacy , HBeAg loss reduction qHBsAg . This study also test whether add-on compare switch PEG-IFN superior , . 2 . STUDY DESIGN This randomize , open-label , active-controlled study evaluate safety efficacy HBeAg loss reduction qHBsAg &gt; 1 log nucleos ( ) ide analogue treat chronic hepatitis B subject treat add PEG ( A ) , switch PEG ( B ) continue nucleos ( ) ide analogue ( C ) 48 week . Patients randomized Arm B one-month overlap period switch exist NA PEG monotherapy . This prevent viral rebound switch . Patients randomize 2:2:1 ratio one 3 treatment arm A , B , C. Arms A B experimental arm . Arm C control arm . 3 . STUDY POPULATION Approximately 255 subject enrol study . 3.1 Inclusion Criteria For entry study , follow inclusion criterion must meet : - Age 21 - 70 year old ( inclusive ) - Male female subject chronic hepatitis B ( ie . presence positive HBsAg HBV DNA least 6 month . - On NA ( lamivudine , adefovir , entecavir tenofovir ) ≥ 1 year - HBV DNA undetected screen - Patient agree take investigational drug systemic anti-viral , cytotoxic , corticosteroid , immunomodulatory agent Chinese traditional remedy unless clinically indicate . - Patient able give write consent prior study start comply study requirement . - Women childbearing age must negative urine ( ß-HCG ) pregnancy test take within 14 day start therapy 3.2 Exclusion Criteria For entry study , follow exclusion criterion must meet : - Patient telbivudine . - Evidence decompensated liver disease define direct ( conjugate ) bilirubin &gt; 1.2xULN , prothrombin time ( PT ) &gt; 1.5x upper limit normal ( ULN ) , serum albumin &lt; 35 g/L , prior history clinical hepatic decompensation ( egs . ascites , encephalopathy , variceal hemorrhage ) . - Evidence hepatocellular carcinoma . - Active co-infection HIV antibody HCV antibody HDV antibody positivity . - Presence viral resistance define virological breakthrough ( &gt; 1 log increase HBV DNA nadir ) presence viral resistance mutation time screen - Absolute neutrophil count &lt; 1.5 X 109/L platelet &lt; 90 x 109/L hemoglobin &lt; 13 g/dL men &lt; 12g/dL woman - Creatinine &gt; 1.5 time upper limit normal creatinine clearance &lt; 60mL/min ( performed central lab ) - Uncontrolled thyroid disease define thyroid-stimulating hormone ( TSH ) &gt; 1.2xULN 0.8xLLN thyroid dysfunction . - Any interferon , Immunomodulators , systemic cytotoxic agent , systemic corticosteroid within 6 month trial entry . - Active substance abuse define DSM-IV , Diagnostic Criteria Drug Alcohol abuse ( appendix 1 ) , opinion investigator would make candidate inappropriate participation study . - History clinically relevant psychiatric disease , seizures , central nervous system dysfunction , severe pre-existing cardiac , renal , hematological disease medical illness investigator 's opinion might interfere therapy . - History autoimmune disease . - Ophthalmological disorder retinopathy , cotton wool spot , optic nerve disorder , retinal hemorrhage , clinically significant abnormality . - Chronic pulmonary disease ( e.g. , chronic obstructive pulmonary disease , interstitial lung disease , pulmonary fibrosis , sarcoidsis ) . - Malignant disease within 5 year trial entry . - Women pregnant practice adequate birth control measure , lactate 4.1 Study Treatment Product , Dose , Mode Administration : Peginterferon α-2b ( PEG ) , 1.5 μg/kg , administer weekly subcutaneous injection specify period time ( see Study Design , Arms A B ) . Pegintron® ( MSD Pharmaceuticals ) . The dosage determine base recommended dose regimen state Pegintron product brochure provide MSD Pharmaceuticals . Reference Therapy , Dose , Mode Administration : Patients exist nucleosid ( ) e analogue therapy comprise lamivudine 100mg daily , adefovir 10mg daily , entecavir 0.5mg 1.0mg daily tenofovir 300mg daily , ( combination thereof ) take oral medication . These provide study protocol . 4.2 Method Assigning Subjects Treatment Randomisation perform computer generate random code ( perform Singapore Clinical Research Institute ) mask allocation sequence . Randomization across treatment arm stratify HBeAg status , type nucleosid ( ) analogue , fibroscan score ( &lt; 8.8 ≥8.8 ) ensure equal distribution across 3 treatment group . 4.3 Blinding/Unblinding There blind therapy study conduct open label study standard interferon clinical trial . 5 . STUDY ASSESSMENTS AND PROCEDURES 5.1 Time Event schedule 5.1.1 . Screening Visit ( Days - 45 1 ) 5.1.2 . Baseline Assessments ( day 1 ) 5.1.3 . Treatment Assessments ( day 2 week 48 ) 5.1.4 . Pegylated-interferon-free Follow-up ( FU ) Visits : FU-Week 1 24 5.2 Clinical Laboratory Tests Hematology : Full blood count ( FBC ) , prothrombin time international normalize ratio ( PT INR ) Chemistry : creatinine , albumin , alkaline phosphatase , aspartate transaminase , alanine transaminase , lactate dehydrogenase , total bilirubin , creatine phosphokinase , alphafetoprotein , ( thyroid stimulate hormone free T4 patient PEG-IFN ) Urinalysis : Protein , Blood , Glucose Viral serology : HBeAg , anti-HBe , HBsAg , qHBsAg anti-HBs 6.0 Efficacy assessment HBeAg qualitative Anti-HBe qualitative HBsAg qualitative HBsAg quantitative HBV DNA ( real time PCR )</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Peginterferon alfa-2b</mesh_term>
	<criteria>Between 21 70 year old . Documented HBsAg positive ≥ 6 month . On nucleos ( ) ide analogue ( lamivudine , adefovir , entecavir tenofovir ) ≥ 1 year HBV DNA undetectable RT PCR screen Patient agree take investigational drug systemic antiviral , cytotoxic , corticosteroid , immunomodulatory agent Chinese traditional remedy unless clinically indicate . Patient able give write consent prior study start comply study requirement . Women childbearing age must negative serum ( ßHCG ) pregnancy test take 14 day start therapy Evidence decompensated liver disease hepatocellular carcinoma . Have follow laboratory test within 4 week study entry : HIV antibody HCV antibody HDV antibody positivity Absolute neutrophil count &lt; 1.5 X 109/l platelet &lt; 90 x 109/l hemoglobin &lt; 13 g/dL men 12g/dL woman serum albumin &lt; 35 g/l serum bilirubin &gt; 30 mg/l creatinine &gt; 1.5 time upper limit normal prothrombin time &gt; 1.5 time control , uncorrected Vitamin K therapy . Any interferon , Immunomodulators , systemic cytotoxic agent , systemic corticosteroid within 6 month trial entry . Prolonged exposure know hepatotoxin alcohol drug . History clinically relevant psychiatric disease , seizures , central nervous system dysfunction , severe preexist cardiac , renal , hematological disease medical illness investigator 's opinion might interfere therapy . Malignant disease within 5 year trial entry . Women pregnant practice adequate birth control measure , lactate</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Hepatitis B virus</keyword>
	<keyword>HBeAg positive</keyword>
	<keyword>HBeAg negative</keyword>
	<keyword>antiviral therapy</keyword>
	<keyword>nucleoside analogue</keyword>
</DOC>